Table 3.
Pathway enrichment analysis of mutual DEGs.
| Category | Term | p-value | Genes |
|---|---|---|---|
| KEGG 2021 Human | Complement and coagulation cascades | 5.38E-06 | C1QB/C1QA/CR2/CFH/PLAU/SERPINE1/CLU |
| Hematopoietic cell lineage | 1.45E-04 | CD2/CR2/ANPEP/IL1R2/CD14/MS4A1 | |
| Nitrogen metabolism | 3.15E-04 | CA12/CA1/CA4 | |
| Cytokine-cytokine receptor interaction | 6.32E-04 | ACVRL1/IL1RN/CCL23/TNFRSF12A/GDF15/IL1R2/OSM/INHBA/CXCL16 | |
| Transcriptional misregulation in cancer | 9.13E-04 | PLAU/IL1R2/ZBTB16/CD14/MMP9/ETV4/ELANE | |
| Prostate cancer | 0.0010972 | PLAU/IL1R2/TCF7/E2F1/MMP9 | |
| Amoebiasis | 0.0013735 | COL1A1/COL1A2/IL1R2/CTSG/CD14 | |
| Protein digestion and absorption | 0.0094521 | COL17A1/COL1A1/COL1A2/COL7A1 | |
| Renin-angiotensin system | 0.0144123 | ANPEP/CTSG | |
| Acute myeloid leukemia | 0.0165684 | ZBTB16/TCF7/CD14 | |
| WikiPathways Human | Complement and coagulation cascades | 3.92E-07 | C1QB/C1QA/CR2/CFH/PLAU/SERPINE1/CLU |
| Mammary gland development pathway - involution (stage 4 of 4) | 5.79E-05 | SOCS3/E2F1/MMP9 | |
| Senescence and autophagy in cancer | 2.00E-04 | COL1A1/GSN/PLAU/SERPINE1/E2F1/INHBA | |
| Vitamin D receptor pathway | 6.67E-04 | CEACAM1/ABCB1/SEMA3B/G0S2/CD14/S100A9/S100A8 | |
| Male infertility | 0.001152 | ABCB1/TCN2/EPSTI1/TRIP13/CLU/MMP9 | |
| Gastric cancer network 1 | 0.0015759 | TPX2/UBE2C/S100P | |
| IL-18 signaling pathway | 0.0015911 | COL1A1/SOCS3/COL1A2/RGS16/ACACB/MMP9/S1PR4/CXCL16 | |
| Type I collagen synthesis in the context of osteogenesis imperfecta | 0.0022987 | COL1A1/ADAMTS2/COL1A2 | |
| Vitamin B12 metabolism | 0.0074793 | TCN2/TCN1/SERPINE1 | |
| Melatonin metabolism and effects | 0.0352811 | PER1/MAOA | |
| Reactome | Immune system | 1.14E-10 | IFITM3/C1QB/C1QA/IL1RN/IFITM1/CFH/KLRB1/TNFAIP6/MAOA/IFI6/CLU/SOCS3/MT2A/CA1/PLAU/ANPEP/S100A12/SLAMF6/CTSG/ELANE/CD177/CR2/GSN |
| Neutrophil degranulation | 7.04E-09 | GSN/TNFAIP6/SLC11A1/HSPA6/RNASE1/MMP9/CEACAM1/PLAU/TCN1/CEACAM6/ANPEP/P2RX1/S100A12/CTSG/S100P/S100A9/S100A8/ELANE/CD177 | |
| Extracellular matrix organization | 9.60E-08 | COL17A1/PCOLCE2/SERPINE1/MMP9/LOXL1/COL1A1/CAPN13/ADAMTS2/CEACAM1/COL1A2/CEACAM6/COL7A1/CTSG/ELANE | |
| Collagen formation | 6.26E-07 | COL17A1/COL1A1/ADAMTS2/COL1A2/PCOLCE2/COL7A1/MMP9/LOXL1 | |
| Regulation of complement cascade 977,606 | 1.50E-06 | C1QB/C1QA/CR2/CFH/CLU/ELANE | |
| Innate immune system | 2.56E-06 | C1QB/C1QA/CR2/GSN/CFH/TNFAIP6/SLC11A1/HSPA6/CLU/RNASE1/MMP9/CEACAM1/PLAU/TCN1/CEACAM6/ANPEP/P2RX1/S100A12/CTSG/S100P/S100A9/S100A8 | |
| Complement cascade | 5.00E-06 | C1QB/C1QA/CR2/CFH/CLU/ELANE | |
| Collagen biosynthesis and modifying enzymes | 1.59E-05 | COL17A1/COL1A1/ADAMTS2/COL1A2/PCOLCE2/COL7A1 | |
| Cytokine signaling in immune system | 4.92E-05 | IFITM3/IL1RN/IFITM1/TNFRSF12A/MAOA/IL1R2/IFI6/MMP9/SOCS3/MT2A/CA1/COL1A2/OAS3/PDCD4/S100A12/CTSG/S100A9 | |
| Metabolism of angiotensinogen to angiotensins | 0.0089463 | ANPEP/CTSG | |
| BioCarta | Granzyme A mediated apoptosis pathway | 0.0039824 | SET/GZMA |
| RB Tumor suppressor/checkpoint signaling in response to DNA damage | 0.0046818 | E2F1/CDK1 | |
| Platelet amyloid precursor protein pathway | 0.0054336 | PLAU/SERPINE1 | |
| Fibrinolysis pathway | 0.0062368 | PLAU/SERPINE1 | |
| Classical complement pathway | 0.0062368 | C1QB/C1QA | |
| Cyclins and cell cycle regulation | 0.0144123 | E2F1/CDK1 | |
| Stathmin and breast cancer resistance to antimicrotubule agents | 0.0156408 | CD2/CDK1 | |
| Cell cycle: G1/S check point | 0.0182269 | E2F1/CDK1 | |
| Erk and PI-3 kinase are necessary for collagen binding in corneal epithelia | 0.02541 | GSN/ZYX | |
| Multi-drug resistance factors | 0.0470557 | ABCB1 |